Investigation on pharmacokinetics, tissue distribution and excretion of a novel platinum anticancer agent in rats by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

References

• Blachley JD, Hill JB. (1981). Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95:628–32
   PubMed Web of Science ®Google Scholar
• Burger H, Zoumaro-Djayoon A, Boersma AW, et al. (2010). Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159:898–908
   PubMed Web of Science ®Google Scholar
• Canetta R, Rozencweig M, Carter SK. (1985). Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12:125–36
   PubMed Web of Science ®Google Scholar
• Cvitkovic E, Bekradda M. (1999). Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26:647–62
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, McBrien DC. (1985). The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity. Biochem Pharmacol 34:1423–8
   PubMed Web of Science ®Google Scholar
• Desoize B, Madoulet C. (2002). Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317–25
   PubMed Web of Science ®Google Scholar
• Fang X, Fang L, Gou S, Cheng L. (2013). Design and synthesis of dimethylaminomethyl-substituted curcumin derivatives/analogues: potent antitumor and antioxidant activity, improved stability and aqueous solubility compared with curcumin. Bioorg Med Chem Lett 23:1297–301
   PubMed Web of Science ®Google Scholar
• Filipski KK, Loos WJ, Verweij J, Sparreboom A. (2008). Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res 14:3875–80
   PubMed Web of Science ®Google Scholar
• Gore ME, Fryatt I, Wiltshaw E, et al. (1989). Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60:767–9
   PubMed Web of Science ®Google Scholar
• Harrap KR. (1985). Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12:21–33
   PubMed Web of Science ®Google Scholar
• Horwich A, Dearnaley DP, Nicholls J, et al. (1991). Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular non-seminomatous germ cell tumors. J Clin Oncol 9:62–9
   PubMedGoogle Scholar
• Jadhav VB, Jun YJ, Song JH, et al. (2010). A novel micelle-encapsulated platinum(II) anticancer agent. J Control Release 147:144–50
   PubMedGoogle Scholar
• Johnsson A, Olsson C, Nygren O, et al. (1995). Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 37:23–31
   PubMed Web of Science ®Google Scholar
• Kizu R, Higashi S, Kidani Y, Miyazaki M. (1993). Pharmacokinetics of (1R, 2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31:475–80
   PubMed Web of Science ®Google Scholar
• Liu QF, Li X, Su Q, et al. (2009). Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats. Arch Pharm Res 32:1621–8
   PubMed Web of Science ®Google Scholar
• Luo FR, Wyrick SD, Chaney SG. (1999). Pharmacokinetics and bio-transformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44:19–28
   PubMed Web of Science ®Google Scholar
• McKeage MJ. (1995). Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228–44
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Mistry P, Ward J, et al. (1995). A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36:451–8
   PubMed Web of Science ®Google Scholar
• Motohashi H, Inui K. (2013). Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 15:581–8
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H, et al. (2002). Gene expression levels and immunolocalization of organic ion transporters in human kidney. J Am Soc Nephrol 13:866–74
   PubMedGoogle Scholar
• O'Dwyer PJ, Stevenson JP, Johnson SW. (2000). Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59:19–27
   PubMed Web of Science ®Google Scholar
• Rixe O, Ortuzar W, Alvarez M, et al. (1996). Oxaliplatin, Tetraplatin, Cisplatin and Carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52:1855–65
   PubMed Web of Science ®Google Scholar
• Rosenberg B, Camp LV, Krigas T. (1965). Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–9
   PubMed Web of Science ®Google Scholar
• Siddik ZH. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Cancer Chemother Pharmacol 22:7265–79
   Google Scholar
• Siddik ZH, Newell DR, Boxall FE, Harrap KR. (1987). The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36:1925–32
   PubMed Web of Science ®Google Scholar
• Sprowl JA, Ness RA, Sparreboom A. (2013). Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet 28:19–27
   PubMed Web of Science ®Google Scholar
• Sun Y, Yin R, Gou S, Zhao J. (2012). Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance. J Inorg Biochem 112:68–76
   PubMed Web of Science ®Google Scholar
• Tashiro T, Kawada Y, Sakurai Y, Kidani Y. (1989). Anti-tumor activity of a new platinum complex, oxalato-(trans-l-1,2-di-aminocyclohexane)platinum(II): new experimental data. Biomed Pharmacother 43:251–60
   PubMed Web of Science ®Google Scholar
• Wang X, Au-Yeung SC, Ho YP. (2007). Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats. J Inorg Biochem 101:909–17
   PubMedGoogle Scholar
• Zhao D, Zhang Y, Xu C, et al. (2012). Pharmacokinetics, tissue distribution and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supra-molecule, in rats and dogs by ICP-MS. Biol Trace Elem Res 148:203–8
   PubMed Web of Science ®Google Scholar